跳至主要内容
临床试验/NCT00123201
NCT00123201已完成2 期

A Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled, Efficacy, Safety and Tolerability Study of Dronabinol MDI in the Acute Treatment of Migraine Headache

Solvay Pharmaceuticals31 个研究点 分布在 1 个国家开始时间: 2005年9月最近更新:
适应症
相关药物

试验速览

阶段
2 期
状态
已完成
试验地点
31

研究概览

简要总结

The primary objective of this study is to evaluate the efficacy and safety of dronabinol MDI for the acute treatment of moderate to severe migraine headache.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Double

入排标准

年龄范围
18 Years 至 65 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Male or female subjects 18 to 65 years, inclusive, with clinically diagnosed migraine with or without aura based on International Headache Society criteria

排除标准

  • Subjects who experience migraine with prolonged aura; familiar hemiplegic migraine; migrainous infarction or basilar migraine; and those with greater than eight migraine attacks per month and/or greater than 14 migraine days per month.

研究者

申办方类型
Industry

研究点 (31)

Loading locations...

相似试验